{"ModuleTitle": "Company Description", "CompanyName": "Cara Therapeutics, Inc.", "Symbol": "CARA", "Address": "4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR, STAMFORD, Connecticut, 06902, United States of America", "Phone": "203-406-3700", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a clinical-stage biopharmaceutical company focused on developing and\r\ncommercializing new chemical entities designed to alleviate pruritus by\r\nselectively targeting peripheral kappa opioid receptors, or KORs. We are\r\ndeveloping a novel and proprietary class of product candidates, led by KORSUVA\r\n(CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in\r\nthe peripheral nervous system and on immune cells.\r\n\r\nIn our KALMTM-1 Phase 3 trial and two Phase 2 trials, KORSUVA\r\n(CR845/difelikefalin) injection (intravenous formulation) has demonstrated\r\nstatistically significant reductions in itch intensity and concomitant\r\nimprovement in pruritus-related quality of life measures in hemodialysis\r\npatients with moderate-to-severe CKD-aP. We are continuing to investigate\r\nKORSUVA (CR845/difelikefalin) injection in our global KALM-2 Phase 3 trial in\r\nhemodialysis patients with moderate-to-severe CKD-aP.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f27%2f0001558370-20-001659.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Derek T. Chalmers", "title": "President, Chief Executive Officer & Director"}, {"name": "FrFdFrique Menzaghi", "title": "Chief Scientific Officer, Senior VP-R&D"}, {"name": "Joana Goncalves", "title": "Chief Medical Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}